Eli Lilly has unveiled plans to invest at least $27bn in building four new pharmaceutical manufacturing sites in the US.
Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...
The challenge for companies is to ensure their local affiliates meet local PV obligations while staying aligned with global PV requirements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback